Loading…
Employees: 193
Size Beijing Luzhu Biotechnology (2480.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $390M, the 825th largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$15.36 on 6 Nov 2026.
Performance Over six months the shares fell 33.1%, against -25.7% for the median peer and -13.4% for the Hong Kong market (cap-weighted) — 8th lowest of 20 in its peer set.
Valuation It trades at 26.1× forward earnings against a peer median of 15.8× (most expensive of 4).
Capital Return on invested capital runs 25.4 points below its cost of capital (5.9% WACC).
Next results Next results expected around 24 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$0 | HK$0 | HK$0 | HK$0 | HK$0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -HK$41.1M | -HK$33.8M | -HK$27.1M | -HK$17.8M | -HK$11.5M |
| EBITDA | -HK$106M | -HK$128M | -HK$190M | -HK$269M | -HK$195M |
| Net income | -HK$150M | -HK$163M | -HK$182M | -HK$276M | -HK$843M |
| Free cash flow | -HK$176M | -HK$211M | -HK$193M | -HK$300M | -HK$387M |
| Capital expenditure | HK$56.3M | HK$66.5M | HK$107M | HK$96.3M | HK$299M |
| Total debt | n/a | HK$304M | HK$71.9M | HK$21.2M | HK$12.6M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 2480.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -3.9% | -14.6% | 5th highest of 21 |
| 6-month return | -33.1% | -25.7% | 8th lowest of 20 |
| Distance from 52-week high | -40.9% | -51.1% | 7th highest of 21 |
| Forward P/E | 26.1× | 15.8× | most expensive of 4 |
| ROIC minus cost of capital | -25.4 pp | -9.1 pp | 5th lowest of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Beijing Luzhu Biotechnology 2480.HK | Hong Kong | $390M | -33% | n/a | n/a | 26.1× | n/a | n/a |
| Onconic Therapeutics 476060.KS | South Korea | $391M | -45% | +179% | 21% | n/a | 2.0% | +725.2% |
| PureTech Health PRTC.L | United Kingdom | $394M | -8% | -4% | -1,617% | n/a | n/a | n/a |
| Zura Bio ZURA | United States | $394M | -15% | n/a | n/a | n/a | n/a | n/a |
| Rznomics 476830.KS | South Korea | $386M | -79% | -72% | -1,440% | n/a | n/a | n/a |
| Editas Medicine EDIT | United States | $395M | -17% | +21% | -178% | n/a | n/a | n/a |
| Guangdong Vtr Bio-Tech 300381.SZ | China | $384M | -23% | -4% | -4% | n/a | n/a | n/a |
| C4 Therapeutics CCCC | United States | $381M | +5% | +2% | -288% | n/a | n/a | n/a |
| Contineum Therapeutics CTNM | United States | $381M | -34% | n/a | n/a | n/a | n/a | n/a |
| Altimmune ALT | United States | $405M | -33% | +55% | -320,726% | n/a | n/a | n/a |
| AgomAb Therapeutics NV ADR AGMB | United States | $376M | -37% | n/a | n/a | n/a | n/a | n/a |
| Edding Genor 6998.HK | Hong Kong | $408M | -45% | +1,418% | 26% | n/a | -15.8% | +197.3% |
| Prothena PRTA | United States | $409M | -26% | +427% | -110% | n/a | n/a | n/a |
| Beijing Kawin Technology Share-Holding 688687.SS | China | $410M | -19% | +3% | 0% | 17.0× | 43.0% | +8.9% |
| G2GBIO 456160.KS | South Korea | $370M | -65% | -45% | -2,884% | n/a | n/a | n/a |
| CorMedix CRMD | United States | $415M | -33% | +280% | 47% | n/a | n/a | n/a |
| Qyuns Therapeutics 2509.HK | Hong Kong | $415M | -17% | +230% | 56% | 10.0× | -20.2% | n/a |
| Kamada KMDA | United States | $417M | -15% | +11% | 14% | 15.8× | 4.1% | +6.5% |
| Surrozen SRZN | United States | $364M | -35% | -9% | -385% | n/a | n/a | n/a |
| Lyell Immunopharma LYEL | United States | $364M | -23% | -55% | -729,281% | n/a | n/a | n/a |
| Zhejiang Laifual Drive 3952.HK | Hong Kong | $363M | n/a | +142% | -11% | n/a | n/a | n/a |